These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes. García-Goñi M; Vázquez Gutiérrez B; Sanmamed MF; Martín-Algarra S; Luis Pérez-Gracia J; Olmedo M; Chumbiauca E; Martín-Calvo N; Galofré JC Endocr Relat Cancer; 2024 Oct; 31(10):. PubMed ID: 39013402 [TBL] [Abstract][Full Text] [Related]
9. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879 [TBL] [Abstract][Full Text] [Related]
10. Survival Among Veterans Receiving Steroids for Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. Van Buren I; Madison C; Kohn A; Berry E; Kulkarni RP; Thompson RF JAMA Netw Open; 2023 Oct; 6(10):e2340695. PubMed ID: 37906189 [TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-related adverse events: Real-world experience from a single veterans' affairs medical center. Benz S; Sherman KA; Dasanu CA; Alvarez-Argote J J Oncol Pharm Pract; 2024 Jun; 30(4):697-704. PubMed ID: 37350125 [TBL] [Abstract][Full Text] [Related]
12. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849 [TBL] [Abstract][Full Text] [Related]
13. Predictors of Rheumatic Immune-Related Adverse Events and De Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor Treatment for Cancer. Cunningham-Bussel A; Wang J; Prisco LC; Martin LW; Vanni KMM; Zaccardelli A; Nasrallah M; Gedmintas L; MacFarlane LA; Shadick NA; Awad MM; Rahma O; LeBoeuf NR; Gravallese EM; Sparks JA Arthritis Rheumatol; 2022 Mar; 74(3):527-540. PubMed ID: 34397169 [TBL] [Abstract][Full Text] [Related]
14. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M; J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586 [TBL] [Abstract][Full Text] [Related]
15. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. Bhatlapenumarthi V; Patwari A; Harb AJ J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736 [TBL] [Abstract][Full Text] [Related]
16. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Kotwal A; Kottschade L; Ryder M Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343 [No Abstract] [Full Text] [Related]
18. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134 [TBL] [Abstract][Full Text] [Related]
19. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162 [TBL] [Abstract][Full Text] [Related]
20. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors. Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]